Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The research firm stated that Telix Pharmaceuticals Limited is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US.

Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available

A robotic arm picking up a product assembly line, displaying the company’s consumer healthcare and wellness offerings.

Telix Pharmaceuticals Limited highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability.

Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix’s enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited’s stock has a consensus price objective of $22.92.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

This article is originally published at Insider Monkey.